The acute respiratory distress syndrome (ARDS) is an important cause of acute respiratory
failure that is often associated with multiple organ failure. Several clinical disorders can …

The advent of mesenchymal stem cell (MSC)-based therapies for clinical therapeutics has
been an exciting and new innovation for the treatment of a variety of diseases associated …

The novel coronavirus disease 2019 (COVID-19) has grown to be a global public health
emergency since patients were first detected in Wuhan, China. Thus far, no specific drugs or …

Mesenchymal stem cells (MSC s) have recently generated great interest in the fields of
regenerative medicine and immunotherapy due to their unique biologic properties. In this …

Background COPD is a devastating disease affecting millions worldwide. As disease
pathogenesis includes both chronic pulmonary and systemic inflammation, antiinflammatory …

Morbidity and mortality have declined only modestly in patients with clinical acute lung injury
(ALI) and acute respiratory distress syndrome (ARDS), despite extensive research into the …

Pericytes and mesenchymal stem cells (MSCs) are ontogenically related, and in fact, no
significant phenotypic differences could be observed by flow cytometry. Transcriptome …

Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic
effects in preclinical models of both acute respiratory distress syndrome (ARDS) and sepsis …

Mortality and morbidity of acute lung injury and acute respiratory distress syndrome remain
high because of the lack of pharmacological therapies to prevent injury or promote repair …

The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies
to the market. To address the demands of the clinical and eventual commercial-scale …